Want to see LRMR full AI Analyst Report?

Larimar Therapeutics (LRMR) Price & Analysis

1,145 Followers

LRMR Stock Chart & Stats

$4.80

-$0.11(-2.78%)

At close: Jan 08 4:00 PM EST

$4.80

-$0.11(-2.78%)

Day’s Range― - ―

52-Week Range$2.72 - $6.42

Previous CloseN/A

Volume147.46K

Average Volume (3M)2.53M

Market Cap

$375.02M

Enterprise Value$128.81M

Total Cash (Recent Filing)$200.38M

Total Debt (Recent Filing)$3.78M

Price to Earnings (P/E)―

Beta1.64

Next Earnings

Aug 06, 2026

EPS Estimate

-0.38

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.10

Shares Outstanding103,882,935

10 Day Avg. Volume3,760,807

30 Day Avg. Volume2,532,667

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)3.56

Price to Sales (P/S)0.00

P/FCF Ratio-2.45

Enterprise Value/Market Cap0.34

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.78

Forecast

1Y Price Target

$12.50

Price Target Upside160.42% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-1.61

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Regulatory Progress: Rolling BLAAlignment with the FDA on using skin frataxin as a surrogate and submission of the first rolling BLA module materially shortens regulatory timelines and creates a clear pathway to potential accelerated approval, increasing the likelihood of a near-term regulatory inflection if data remain supportive.

Durable Clinical SignalsPersistent biomarker increases and directional functional gains across an 18‑month open‑label dataset suggest disease‑modifying potential rather than transient effects. Durable target engagement and functional trends strengthen the scientific case for approval and future payer/clinician adoption if confirmed in confirmatory trials.

Near-term Cash Runway After FinancingA post‑offering cash balance providing runway into mid‑2027 materially reduces immediate financing urgency while the company advances BLA modules and initiates a global Phase 3, enabling execution of regulatory and clinical milestones without near‑term dilution pressure if burn trends hold.

Bears Say

Accelerating Cash BurnRising operating and free cash burn highlights structural funding needs; accelerating negative cash flow increases reliance on external financing or partnerships, which can dilute shareholders or constrain strategic options if clinical or regulatory setbacks lengthen development timelines.

Pre‑revenue Development ProfileAbsence of product revenue means the company’s long‑term sustainability depends entirely on successful clinical development and external capital. Large, sustained net losses without diversification of income elevate execution risk and make balance sheet and financing strategy central to survival.

Safety And Tolerability RisksHigh discontinuation rates and frequent severe allergic events in a small program raise structural safety and labeling risks that can affect regulatory approval conditions, prescriber adoption, and commercial uptake; mitigation may require risk‑management strategies or limit indications.

Larimar Therapeutics News

Closing Bell Movers: Levi Strauss down 6% on earnings

Investors bought the early-session dip in the Tech space on Wednesday, helping the sector join Energy as the...

1d ago

AZZ

Larimar Therapeutics director buys $167K in common stock

In a regulatory filing, Larimar Therapeutics (LRMR) disclosed that its director, Thomas Hamilton, bought 50,000 shares of common...

1d ago

LRMR

Citizens biotech analysts hold an analyst/industry conference call

Biotech Analysts discuss Friedreich’s Ataxia developments from the patient community perspective (relevant companies LRMR SLDB BIIB PTCT LXEO...

7d ago

BIIB

DSGN

Larimar Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Larimar Therapeutics (LRMR) with a Buy rating and $10 price target The company’s...

8d ago

LRMR

Larimar Therapeutics price target lowered to $5 from $7 at Baird

Baird analyst Christopher Chen lowered the firm’s price target on Larimar Therapeutics (LRMR) to $5 from $7 and...

10d ago

LRMR

Larimar Therapeutics selloff a buying opportunity, says Citi

Citi recommends buying Larimar Therapeutics (LRMR) shares on yesterday’s weakness. FDA feedback indicates the company’s current data package...

10d ago

LRMR

Midday Fly By: SpaceX to join Nasdaq-100, Comcast to split into two companies

The major averages were broadly higher near noon as investors await news out of the Middle East after...

10d ago

CRM

Larimar stumbles on safety news even as BLA submission kicks off

Larimar Therapeutics (LRMR) shares slid on Monday after the company reported new safety findings from its open label...

11d ago

LRMR

Larimar Therapeutics submits first module of rolling BLA for nomlabofusp

Larimar Therapeutics (LRMR) announced it has submitted the first module of its rolling Biologics License Application submission to...

11d ago

LRMR

Adobe, Larimar, Palantir, Chevron, eXp Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($ADBE) ), ( ($LRMR) ), ( ($PLTR) ), ( ($CVX)...

6d ago

CVX

ADBE

Larimar Therapeutics: Buy Rating on Nomlabofusp’s Robust FA Efficacy and De-Risked Regulatory Pathway

William Blair analyst Myles Minter has reiterated their bullish stance on LRMR stock, giving a Buy rating today....

10d ago

LRMR

Nomlabofusp Progress and Durable Efficacy Support Buy Rating on LRMR with Unchanged $25 Price Target

In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on Larimar Therapeutics, with...

10d ago

LRMR

Larimar Advances Nomlabofusp BLA Toward Accelerated Approval

Larimar Therapeutics ( ($LRMR) ) just unveiled an announcement. On June 29, 2026, Larimar Therapeutics reported that it...

11d ago

LRMR

Larimar Therapeutics: Buy Rating Reaffirmed as Nomlabofusp Regulatory Catalysts and Data Updates Support Steady $14 Price Target and 280% Upside

Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Larimar Therapeutics. The associated price target is...

11d ago

LRMR

LRMR FAQ

What was Larimar Therapeutics, Inc.’s price range in the past 12 months?

Larimar Therapeutics, Inc. lowest stock price was $2.71 and its highest was $6.42 in the past 12 months.

What is Larimar Therapeutics, Inc.’s market cap?

Larimar Therapeutics, Inc.’s market cap is $375.02M.

When is Larimar Therapeutics, Inc.’s upcoming earnings report date?

Larimar Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 27 days.

How were Larimar Therapeutics, Inc.’s earnings last quarter?

Larimar Therapeutics, Inc. released its earnings results on May 14, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.535 by $0.225.

Is Larimar Therapeutics, Inc. overvalued?

According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Larimar Therapeutics, Inc. pay dividends?

Larimar Therapeutics, Inc. does not currently pay dividends.

What is Larimar Therapeutics, Inc.’s EPS estimate?

Larimar Therapeutics, Inc.’s EPS estimate is -0.38.

How many shares outstanding does Larimar Therapeutics, Inc. have?

Larimar Therapeutics, Inc. has 103,882,935 shares outstanding.

What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?

Larimar Therapeutics, Inc. reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.535. Following the earnings report the stock price went down -5.122%.

Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?

Currently, no hedge funds are holding shares in LRMR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Larimar Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-134.14%

Trailing 12-Months

Asset Growth

22.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Larimar Therapeutics, Inc.

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Larimar Therapeutics (LRMR) Earnings & Revenues

Historic Earnings Reports

LRMR Stock 12 Month Forecast

Average Price Target

$12.50

▲(160.42% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.21,4.886153846153846,6.562307692307693,8.23846153846154,9.914615384615384,11.59076923076923,13.266923076923078,14.943076923076923,16.619230769230768,18.295384615384616,19.97153846153846,21.647692307692306,23.323846153846155,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.21,3.9246153846153846,4.639230769230769,5.3538461538461535,6.068461538461538,6.783076923076923,7.497692307692307,8.212307692307693,8.926923076923076,9.64153846153846,10.356153846153845,11.07076923076923,11.785384615384615,{"y":12.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.21,3.3476923076923075,3.4853846153846155,3.623076923076923,3.7607692307692306,3.8984615384615386,4.036153846153846,4.173846153846154,4.311538461538461,4.44923076923077,4.586923076923076,4.724615384615385,4.862307692307692,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.89,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.81,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.23,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.68,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.94,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.21,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >